GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Cullinan Therapeutics Inc (NAS:CGEM) » Definitions » Tax Rate %

CGEM (Cullinan Therapeutics) Tax Rate % : -0.25% (As of Dec. 2024)


View and export this data going back to 2021. Start your Free Trial

What is Cullinan Therapeutics Tax Rate %?

Tax Rate % is calculated as Tax Expense divided by its Pre-Tax Income. Cullinan Therapeutics's Tax Expense for the three months ended in Dec. 2024 was $0.12 Mil. Cullinan Therapeutics's Pre-Tax Income for the three months ended in Dec. 2024 was $-47.53 Mil. Therefore, Cullinan Therapeutics's Tax Rate % for the quarter that ended in Dec. 2024 was -0.25%.

Cullinan Therapeutics Tax Rate % Historical Data

The historical data trend for Cullinan Therapeutics's Tax Rate % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cullinan Therapeutics Tax Rate % Chart

Cullinan Therapeutics Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Tax Rate %
Get a 7-Day Free Trial - - 27.84 8.35 -0.07

Cullinan Therapeutics Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
Tax Rate % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 35.59 - - - -0.25

Cullinan Therapeutics Tax Rate % Calculation

Tax Rate % is the ratio of tax expense divided by pretax income, usually presented in percent.

Cullinan Therapeutics's Tax Rate % for the fiscal year that ended in Dec. 2024 is calculated as

Tax Rate %=Tax Expense (A: Dec. 2024 )/Pre-Tax Income (A: Dec. 2024 )
=0.117/-167.458
=-0.07 %

Cullinan Therapeutics's Tax Rate % for the quarter that ended in Dec. 2024 is calculated as

Tax Rate %=Tax Expense (Q: Dec. 2024 )/Pre-Tax Income (Q: Dec. 2024 )
=0.117/-47.53
=-0.25 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Cullinan Therapeutics Tax Rate % Related Terms

Thank you for viewing the detailed overview of Cullinan Therapeutics's Tax Rate % provided by GuruFocus.com. Please click on the following links to see related term pages.

Cullinan Therapeutics Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Cullinan Therapeutics Inc (NAS:CGEM) » Definitions » Tax Rate %
Comparable Companies
ORKA PGEN MNMD VERV RLAY PHAT TBPH OMER AUTL CRMD VRTX ASX:CSL REGN XKRX:207940 XBRU:ARGX ALNY XBRU:UCB ONC XKRX:068270 BNTX
Traded in Other Exchanges
N/A
Address
One Main Street, Suite 1350, Cambridge, MA, USA, 02142
Website
https://cullinantherapeutics.com
Cullinan Therapeutics Inc is a biopharmaceutical company. It has a diversified portfolio of clinical-stage assets that inhibit key drivers of disease or harness the immune system to eliminate diseased cells in both oncology and autoimmune diseases. Its understanding of oncology, immunology, and translational medicine, creates differentiated ideas, identifies the appropriate targets, and selects the optimal modality to develop transformative therapeutics across a variety of cancer and autoimmune indications. It has one reporting and one operating segment, which is the business of developing immunology and oncology therapies.
Executives
Jacquelyn L Sumer officer: Chief Legal Officer C/O GENOCEA BIOSCIENCES, INC., 100 ACORN PARK DRIVE 5TH FLOOR, CAMBRIDGE MA 02140
Nadim Ahmed director, officer: President and CEO C/O CELGENE CORPORATION, 86 MORRIS AVENUE, SUMMIT NJ 07901
Jeffrey Alan Jones officer: Chief Medical Officer ONE MAIN STREET, SUITE 520, CAMBRIDGE MA 02142
Jennifer Michaelson officer: See Remarks C/O CULLINAN MANAGEMENT, INC., ONE MAIN STREET SUITE 520, CAMBRIDGE MA 02142
Savill Corrine officer: Acting Chief Business Officer C/O CULLINAN ONCOLOGY, LLC, ONE MAIN STREET SUITE 520, CAMBRIDGE MA 02142
Jeffrey Trigilio officer: Chief Financial Officer C/O CULLINAN MANAGEMENT, INC., ONE MAIN STREET, SUTIE 520, CAMBRIDGE MA 02142
David P. Ryan director C/O CULLINAN ONCOLOGY, INC., ONE MAIN STREET, SUITE 520, CAMBRIDGE MA 02142
Vision Scs F2 10 percent owner 74 GRAND RUE, LUXEMBURG N4 L-1660
F2 Bioscience I 2017 Ltd 10 percent owner 8, RUE SAINT-LEGER, GENEVA V8 CH 1205
Biotechnology Value Fund L P other: See Explanation of Responses 44 MONTGOMERY STREET, 40TH FL, SAN FRANCISCO CA 94104
Anne-marie Martin director ONE MAIN STREET, SUITE 520, CAMBRIDGE MA 02142
Biotechnology Value Trading Fund Os Lp other: See Explanation of Responses P.O. BOX 309 UGLAND HOUSE, GRAND CAYMAN E9 KY1-1104
Bvf Partners Os Ltd. other: See Explanation of Responses P.O. BOX 309 UGLAND HOUSE, GRAND CAYMAN E9 KY1-1104
Mark N Lampert 10 percent owner 1 SANSOME ST, 30TH FL, SAN FRANCISCO CA 94104
Bvf I Gp Llc other: See Explanation of Responses 44 MONTGOMERY ST., 40TH FLOOR, SAN FRANCISCO CA 94104